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Idiopathic pneumonia syndrome (IPS) is a fatal non-infectious respiratory complication that develops after hematopoietic
stem cell transplantation (HSCT). Because of the poor prognosis of post-HSCT patients with IPS requiring mechanical
ventilatory support, performing extracorporeal membrane oxygenation (ECMO) has been regarded as relatively
contraindicated in these patients. A tumor necrosis factor-alpha inhibitor, etanercept, has been reported to be a
promising treatment option for post-HSCT patients with IPS; however, the phase III clinical trial of etanercept has
recently been terminated without definitive conclusion. If post-HSCT patients with IPS really benefit from etanercept,
mechanical ventilation (MV)-dependent IPS patients might be worth receiving ECMO treatment in line with the protective
lung strategy. We therefore performed veno-venous ECMO (VV-ECMO), which substantially acted as an extracorporeal
carbon dioxide removal, on a 56-year-old post-HSCT male with severe MV-dependent IPS due to graft-versus-host disease.
Although a serious bleeding complication due to post-HSCT thrombocytopenia occurred, the VV-ECMO was continued
for 11 days. The patient successfully entered remission of the IPS and was finally extubated on the 12th MV day. However,
the patient soon complained of dyspnea, probably due to cytomegalovirus infection and/or exacerbation of the IPS, and
was reintubated after 3 days of extubation. The patient then rapidly developed irreversible type II respiratory failure
despite the administration of etanercept and an anti-cytomegalovirus agent and died on the eighth re-MV day. The
autopsy findings of the patient revealed diffuse alveolar damage and alveolar hemorrhage, accompanied with
bronchitis obliterans in his lungs, as well as whole body cytomegalovirus infection, which were compatible with
the clinical diagnosis of the patient. We think that the legitimacy of this treatment strategy is dependent on the
overall prognosis of IPS, which is influenced by the complications induced by immunosuppressants and ECMO,
especially infections and bleeding.
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Figure 1 Computed tomography scans of the patient taken on
the first ICU day. These images show the widespread bilateral
peripheral field-dominant patchy consolidations accompanied with
diffuse ground glass opacity.
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Patients with hematological malignancies after hematopoietic
stem cell transplantation (HSCT) often suffer from respira-
tory complications [1], and those who require mechanical
ventilation (MV) are known to have a poor prognosis [2].
Idiopathic pneumonia syndrome (IPS), one of the non-
infectious respiratory complications that occurs after
HSCT, is regarded as an extremely life-threatening condi-
tion, and its prevalence is estimated to be 3% to 15% in
post-HSCT patients [3]. In particular, MV-dependent post-
HSCT patients with IPS have been reported to have a 95%
to 100% mortality rate [4-6].
Recently, the effectiveness of a tumor necrosis factor-
alpha (TNF-alpha) inhibitor, etanercept, has been aggres-
sively studied to post-HSCT IPS patients [7-9], and thus,
MV-dependent IPS patients may also benefit from etaner-
cept treatment [7,8]. Therefore, a lung-protective strategy
for MV-dependent IPS patients is considered to be
important to avoid volutrauma and/or ventilator-induced
lung injury (VILI) until etanercept can exert its effects.
The usefulness of extracorporeal membrane oxygen-
ation (ECMO) for acute respiratory distress syndrome
(ARDS) has been reported in recent years [10], but in
general, ECMO is considered to be ineffective for patients
with malignancies [11,12], and the post-HSCT patients
with respiratory complications have been regarded to be
relatively contraindicated for ECMO [13]. However, if
post-HSCT patients with IPS exhibit an improvement or
reversal of their condition by the administration of etaner-
cept, MV-dependent IPS patients might be worth receiving
ECMO treatment in line with a lung-protective strategy.
We herein report a post-HSCT case with IPS, in whom
we performed veno-venous ECMO (VV-ECMO) because
the patient was expected to have a reversal of his condi-
tion by the induction treatment with a TNF-alpha
inhibitor. To the best of our knowledge, only one very
recent case report has been published on an IPS patient
who underwent VV-ECMO [14], so our report will be
the first on a post-HSCT patient with IPS who was con-
currently treated with VV-ECMO and a TNF-alpha
inhibitor.
Case presentation
A 56-year-old male had developed nephrotic syndrome due
to primary amyloidosis 12 years earlier and had gone into
complete remission following melphalan-prednisone the-
rapy. However, after continuing the melphalan-prednisone
therapy for about 10 years, bicytopenia was detected, and
he was diagnosed with chronic myelomonocytic leukemia
and underwent allogenic bone marrow transplantation
(BMT) from a human leukocyte antigen identical sibling
donor 11 months prior to his presentation at our hospital.
The engraftment of hematopoietic stem cells was observed
24 days after BMT, and acute graft-versus-host disease(GVHD) was not observed while the patient was being
treated using cyclosporine as an immunosuppressant. How-
ever, the follow-up chimerism analysis revealed the survival
of recipient-derived cells, so the cyclosporine was reduced
in the hopes of inducing a graft-versus-leukemia (GVL)
effect approximately 4 months after the BMT. The
cyclosporine was then gradually decreased and discon-
tinued, and the recipient-derived cells almost disappeared
due to the GVL effect.
One month before the intensive care unit (ICU)
admission, he suffered from an influenza A infection and
developed dyspnea with GVHD exacerbation. Cyclosporine
re-administration was initiated for the GVHD aggravation,
and concurrently, antibiotics, antifungal agents, and
antiviral agents were introduced empirically. Despite these
therapies, his respiratory symptoms got worse, and he was
transferred to the ICU. A computed tomography (CT)
examination of his chest revealed bilateral peripheral
dominant patchy consolidations accompanied with diffuse
ground glass opacity (Figure 1).
On admission to the ICU, tachypnea (respiratory rate
36/min) and dyspnea with a low oxygen saturation value
by pulse oximetry were observed. We considered that
the patient might be suffering from IPS because of the
GVHD-related respiratory symptoms, so high-dose
methylprednisolone therapy (1 g/day for three days)
under non-invasive positive pressure ventilation was
initiated from the first ICU day. Unfortunately, that
night, the patient developed severe hypoxemia and his
consciousness rapidly deteriorated, so he was finally
intubated and received MV (Figure 2). The initial MV
mode was biphasic positive airway pressure, with an
inspiratory fraction of oxygen (FIO2) of 0.8, a peak
inspiratory pressure (PIP) of 28 cmH2O, positive end-
expiratory pressure (PEEP) of 10 cmH2O, respiratory
frequency of 15/min and tidal volume of around 6 ml/
ideal body weight (BW). However, as his spontaneous






































Figure 2 The ICU course of the patient. BIPAP bilevel positive airway pressure, FIO2 fraction of inspired oxygen, mPSL methylprednisolone, Nasal
HF nasal high flow system, NPPV non-invasive positive pressure ventilation, PaCO2 partial pressure of carbon dioxide, PaO2 partial pressure of
oxygen, PEEP positive end-expiratory pressure, PIP peak inspiratory pressure, PSV pressure support ventilation, sPSL soluble prednisolone, VV-ECMO
veno-venous extracorporeal membrane oxygenation.
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http://www.jintensivecare.com/content/2/1/48poor oxygenation and respiratory acidosis (pH 7.159,
PaCO2 77.4 mmHg, HCO3
− 27.8 mmol/l, PaO2/FIO2
135), along with his poor lung compliance (lung comp-
liance 18 ml/cm H2O), his strong inspiratory effort
generated a large tidal volume up to 10 ml/ideal BW
and an asynchrony with the ventilator was observed. His
large tidal volume and asynchrony were sustained
irrespective of deep sedation and ventilator setting
changes, raising concerns about volutrauma and/or VILI.
As he already fulfilled the severity criteria for VV-
ECMO due to his Murray's score of 3.25 points on the
following day, we decided to introduce ECMO therapy
with an expectation of a recovery in his lung injury by
the administration of etanercept for the IPS.
After obtaining informed consent, the patient was can-
nulated with a 19 Fr. cannula for venous drainage into
his right femoral vein and a 15 Fr. cannula for oxygen-
supplemented blood infusion into his right internal jugu-
lar vein. Due to the narrow vascular size of the patient,
the catheters we used were smaller in diameter than the
general recommendation of VV-ECMO. Because of this
small diameter, the ECMO session was initiated with an
extracorporeal blood flow of 1.5 to 2 l/min, which was
relatively low flow rate, with a sweep gas flow of 2 l/min
at 80% oxygen (centrifugal pump, CAPIOX® SP101
PLUS; oxygenator, CAPIOX® LX, TERUMO, Tokyo,
Japan), and anticoagulation therapy with unfractionated
heparin was initiated to maintain an activated clotting
time over 150 s.
Soon after the induction of VV-ECMO, the patient
was performed bronchoalveolar lavage (BAL) and con-
firmed to have IPS without any active pulmonary infec-
tions based on BAL fluid testing 72 h later, so we
administered etanercept subcutaneously at a dose of 16mg (0.4 mg/kg) twice a week from the fifth ICU day,
accompanied by methylprednisolone consolidation therapy
(80 mg/day for 7 days and 40 mg/day for the subsequent 7
days). During the ECMO session, he was administered with
adequate sedatives and analgesics, and pressure support
(PS) ventilation was used with a PEEP of 10 cmH2O, PS of
5 cmH2O, and FIO2 of 0.3, so as to maintain lung-rest and
prevent alveolar collapse. A few days after the administra-
tion of etanercept, his oxygenation was ameliorated up to
PaO2/FIO2 353 mmHg in spite of the low extracorporeal
flow rate; nevertheless, his chest X-p showed no sign of im-
provement of the bilateral consolidations. Therefore, we
considered that the patient still had not entered the remis-
sion phase of IPS and continued the VV-ECMO, which
was substantially acted as ‘extracorporeal carbon dioxide
removal (ECCO2R)’ , in line with a lung-protective strategy.
After further several days, the consolidations in his bilateral
lung field almost vanished (Figure 3), so we considered that
he had successfully entered remission from the IPS.
On the other hand, he suffered from severe bleeding
complications from the vascular access sites used for ECMO,
probably due to post-HSCT-related thrombocytopenia,
which persisted at less than 2 × 104/μl, and transfusions
of platelet concentrate and packed red blood cells were
required almost every day during the ECMO session.
On the 12th ICU day (the 11th VV-ECMO day), the
patient was withdrawn from the ECMO without venti-
lator setting changes and was successfully extubated on
the 13th ICU day. A blood gas analysis performed just
before the extubation showed improved oxygenation
(pH 7.444, PaCO2 46.5 mm Hg, HCO3
− 31.2 mmol/l,
PaO2/FIO2 294) under pressure support ventilation
with a PEEP of 5 cmH2O, PS of 5 cmH2O and FIO2 of
0.4 (Additional file 1: Table S1).
Figure 3 Computed tomography scans of the patient taken on
the 12th ICU day. These images show the amelioration of the
consolidations of the bilateral lung fields.
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severe cough beginning the day after extubation, and his
oxygen saturation was deteriorating despite oxygen
therapy, he received a humidified high-flow nasal cannula
on the 14th ICU day. As his chest radiography study
revealed an exacerbation of the bilateral consolidation,
and his blood sample examination revealed seropositivity
for the cytomegalovirus antigen, the patient was con-
sidered to have developed cytomegalovirus pneumonia
and/or an exacerbation of the remitted IPS. Despite the
concurrent administration of an anti-cytomegalovirus agent
and etanercept, his oxygenation worsened and he required
both reintubation and MV support on the 16th ICU day. A
few days later, he developed type II respiratory failure, and
he died on the 22nd ICU day. The autopsy findings
revealed diffuse alveolar damage and alveolar hemorrhage,
accompanied with bronchitis obliterans in his lung, as well
as whole body cytomegalovirus infection, which were com-
patible with the clinical diagnosis of the patient.Discussion
In 1993, the definition of IPS was proposed as a wide-
spread alveolar injury after HSCT in the absence of
active lower respiratory tract infection, which was based
upon a BAL examination or lung biopsy, without cardio-
genic causes of pulmonary dysfunction [3]. Many factors,
such as the use of chemotherapies before BMT, GVHD,
and various other factors, including the hematopoietic
stem cell donor characteristics, were identified as risk
factors for IPS, and it was revealed that TNF-alpha also
participates in the onset of IPS [4]. In recent years, a
positive impact of a TNF-alpha inhibitor, etanercept, on
post-HSCT patients with IPS was reported [7,8], and a
phase III clinical trial of etanercept for IPS is conducted
[9]. Unfortunately, this trial was not able to show the
effectiveness of etanercept for post-HSCT patients with
IPS, the definitive conclusion should not be made basedon this trial alone because of its inadequate power and
small sample size.
According to the report of the Extracorporeal Life
Support Organization (ELSO) registry, the results of
ECMO for severe respiratory failure in adult patients
with malignancy were extremely poor [11]. That study
included four adult post-HSCT cases; however, the ELSO
registry concluded that it is impossible to make any
recommendations because of the small number of cases.
The ELSO registry also reported that the result of
ECMO for the severe respiratory failure of pediatric
post-HSCT patients was extremely poor [12]. Therefore,
performing ECMO for post-HSCT patients with severe
respiratory failure has been generally considered to be
relatively contraindicated by these reports [13]. However,
although four adult post-HSCT patients were included
in the ELSO report and all had indication of ECMO for
pulmonary support [11], there was no mention about
their individual causes of respiratory failure, and thus,
we have no information about whether these patients
suffered from IPS or other diseases. Conversely, a first
case report which performed VV-ECMO for an MV-
dependent IPS patient was recently published [14]. That
paper reported the successful use of VV-ECMO along
with conventional treatment for IPS, mainly by gluco-
corticoid administration, without etanercept. This case
report might show the usefulness of the lung rest intro-
duced by ECMO in MV-dependent IPS patients.
Although it is not known whether the results of the
CESAR trial [10], which showed the usefulness of VV-
ECMO for ARDS, are applicable for other types of se-
vere respiratory failure, such as IPS, we applied the entry
criteria of the CESAR trial, especially the Murray's score
[15] ≥3 points, to determine whether to introduce VV-
ECMO in our case, as it was the only reported case of
the successful use of VV-ECMO for IPS [14]. According
to the Berlin definition of ARDS [16], however, this case
was defined as not the ‘severe type’ but the ‘moderate
type’ of ARDS and generally recommended less invasive
respiratory supports than ECMO. However, considering
the extremely poorer prognosis of MV-dependent IPS
patients compared with even ‘severe’ ARDS in the Berlin
definition (mortality, 95%–100% [4-6] vs. 45% [16]), we
assume that vulnerabilities of MV-dependent IPS patients
would be underestimated when we applied this definition
to IPS patient population. Moreover, because of our several
experiences of IPS patients equivalent to ‘moderate’ ARDS
prior to this case, whom were easily complicated VALI in
spite of the conventional lung-protective MV setting, we
decided to introduce VV-ECMO after due consideration.
Because ECMO is a highly invasive and expensive treat-
ment, it is necessary to judge the indications carefully.
Even if using ECMO for IPS is valid to prevent VILI, as
was suggested in the aforementioned case report [14], the
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alternatives, which are less invasive and/or less expen-
sive than ECMO, is essential. In particular, it is impor-
tant to take into consideration the risk of hemorrhagic
complications, which may be induced by anticoagula-
tion therapy and serious post-HSCT thrombocytopenia,
as was seen in our case.
The reason why the patient exhibited aggravated symp-
toms soon after the extubation may have included not only
a re-exacerbation of IPS but also the cytomegalovirus
infection. If the immunosuppression induced by etaner-
cept, along with the high-dose methylprednisolone therapy,
is excessive, the concurrent treatment with the induction
of etanercept and VV-ECMO for post-HSCT patients with
IPS may be considered as a relative contraindication, as is
mentioned in the ELSO registry guideline [13].
Although some unresolved problems exist, such as
uncertainty of the efficacy of etanercept and VV-ECMO
for IPS, the risks of immunosuppression generated by eta-
nercept and other immunosuppressants and the bleeding
tendency due to post-HSCT-related thrombocytopenia, we
consider that the usefulness of concurrent therapy of
immunosuppressants including etanercept and ECMO for
IPS deserves an evaluation. However, it should be evaluated
by not only the short-term prognosis, such as IPS remission
or MV withdrawal, but also the long-term prognosis, such
as the overall survival.
Conclusions
To the best of our knowledge, our case is the second
reported post-HSCT patient with IPS on MV who under-
went VV-ECMO. In addition, this is the first case treated
with concurrent etanercept and VV-ECMO for MV-
dependent IPS. We think that the legitimacy of this treat-
ment strategy is dependent on the overall prognosis of
IPS, which is influenced by the complications induced by
immunosuppressants including etanercept and ECMO,
especially infections and bleeding. Further studies on this
treatment modality are anticipated in the future.
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